Recombinant Human ASGR1/ASGPR1 Protein, CF

• Reactivity: Hu
• Applications: Binding Activity
• Format: Carrier-Free

Recombinant Human ASGR1/ASGPR1 Protein, CF Summary

• Additional Information: His-tag
• Details of Functionality: Measured by its binding ability in a functional ELISA. rhASGPR1 immobilized at 2.5 µg/mL (100 µL/well) on a Mouse Anti-polyHistidine Monoclonal Antibody (Catalog # MAB050) coated plate can bind biotinylated beta -Gal-NAc-PAA with a linear range of 5‑300 ng/mL.
• Source: Mouse myeloma cell line, NS0-derived human ASGR1/ASGPR1 protein
  Gln62-Leu291, with an N-terminal 9-His tag
• Accession #: P07306
• N-terminal Sequence: His
• Protein/Peptide Type: Recombinant Proteins
• Gene: ASGR1
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Binding Activity
• Theoretical MW: 27.6 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 38 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human ASGR1/ASGPR1 Protein, CF

• ASGPR 1
• ASGP-R 1
• ASGPR
• ASGPR1
• ASGR1
• asialoglycoprotein receptor 1
• CLEC4H1
• CLEC4H1ASGPR1
• C-type lectin domain family 4 member H1
• Hepatic lectin H1
• HL-1
• MHL1
• RHL1

Background

The human asialoglycoprotein receptor (ASGPR) is an endocytic recycling receptor that belongs to the long-form subfamily of the C-type/Ca⁺²-dependent lectin family (1, 2, 3). It is a complex of two noncovalently-linked subunits, a major 46 kDa glycoprotein (ASGR1) and a minor 50 kDa glycoprotein (ASGR2). The major human ASGPR subunit, ASGR1 (also H1), is synthesized as a 291 amino acid (aa) type II transmembrane (TM) glycoprotein. It contains a 40 aa cytoplasmic region, a 21 aa TM segment, and a 230 aa extracellular domain (ECD) (4 - 6). The cytoplasmic region contains one palmitoylation site at Cys36 that is essential for ligand endocytosis and dissociation (7). The ECD contains two important structural regions. The first is a stalk region of 62 aa (aa 61 - 123) that contributes to noncovalent oligomerization. The second is a 118 aa, carbohydrate-binding, Ca⁺²-dependent C-type lectin domain (aa 161 - 278) that is stabilized by three Ca⁺² ions (3, 8). Human ASGR1 ECD is 79% aa identical to mouse ASGR1 ECD. There are two minor (ASGR2) subunits that interact with ASGR1/H1 in a mutually exclusive manner to generate a functional ASGPR (9). They represent alternate splice forms of a type II TM protein. Termed H2b and H2c, H2b differs from H2c only by the presence of a 19 aa insert in its cytoplasmic region. This insert is significant because it allows serine phosphorylation of the cytoplasmic tail and provides for the majority of ASGPR ligand internalization (9). The stoichiometry of a functional ASGPR is unclear, but is suggested to be either a 2:2, 3:1 or 3:2 ratio of ASGR1/H1:ASGR2/H2 (9, 10, 11). ASGPR is found on hepatocytes and a subset of T cells (6, 12). ASGPR is reported to bind Gal (nonreducing), GalNAc, and sialic acid alpha 2,6Gal and GalNAc (3, 13, 14, 15). This is generally within the context of triantennary or tetraantennary configurations (2). The sialic acid terminations are of particular interest because molecules with these motifs most likely represent the endogenous ligands for ASGPR (14).

1. Stockert, R. J. (1995) Physiol. Rev. 75:591.
2. Weigel, P.H. and J.H.N. Yik (2002) Biochim. Biophys. Acta 1572:341.
3. Meier, M. et al. (2000) J. Mol. Biol. 300:857.
4. Spiess, M. et al. (1985) J. Biol. Chem. 260:1979.
5. Spiess, M. and H.F. Lodish (1986) Cell 44:177.
6. Bischoff, J. et al. (1988) J. Cell Biol. 106:1067.
7. Yik, J.H.N. et al. (2002) J. Biol. Chem. 277:40844.
8. Monroe, R.S. and B.E. Huber (1994) Gene 148:237.
9. Yik, J.H.N. et al. (2002) J. Biol. Chem. 277:23076.
10. Bider, M.D. et al. (1996) J. Biol. Chem. 271:31996.
11. Lodish, H. (1991) Trends Biochem. Sci. 16:374.
12. Park, J-H. et al. (2006) Biotechnol. Lett. 28:1061.
13. Westerlind, U. et al. (2004) Glyconj. J. 21:227.
14. Park, E.I. et al. (2005) Proc. Natl. Acad. Sci. USA 102:17125.
15. Park, E.I. et al. (2003) J. Biol. Chem. 278:4597.

Publications for ASGPR1 (4394-AS)(1)

Publication using 4394-AS

• LL Eggink, KF Roby, R Cote, J Kenneth Ho An innovative immunotherapeutic strategy for ovarian cancer: CLEC10A and glycomimetic peptides J Immunother Cancer, 2018-04-17;6(1):28. 2018-04-17 [PMID: 29665849] (Binding Assay, Human)

Bioinformatics

• Gene Symbol: ASGR1
• Uniprot:
  • P07306()